Previous 10 | Next 10 |
2023-11-01 12:30:34 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q3 2023 Earnings Call Nov 01, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript
2023-11-01 10:40:24 ET Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript November 01, 2023, 08:00 AM ET Company Participants Jordan Zwick - SVP, Business Development & IR Patrick Holt - President & CEO Tom Reilly - CFO Conference Call P...
2023-11-01 07:08:48 ET More on Amarin Amarin Corporation plc (AMRN) Cantor Fitzgerald Annual Global Healthcare Conference (Transcript) Amarin's Financial Tug-Of-War: Vascepa Vs. Generics Amarin Q3 2023 Earnings Preview Jefferies downgrades Amarin to 'hold'; s...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations 1 ; Quarter-Ending Cash Position of $321 Million -- -- Company C...
Amarin Corporation plc (AMRN) is expected to report $-0.05 for Q3 2023
2023-10-31 12:06:44 ET More on Amarin Amarin Corporation plc (AMRN) Cantor Fitzgerald Annual Global Healthcare Conference (Transcript) Amarin's Financial Tug-Of-War: Vascepa Vs. Generics Jefferies downgrades Amarin to 'hold'; shares down Amarin in deal with N...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research from the landmark REDUCE-IT cardiovascular outcomes trial on the effects of VASCEPA ® /VAZKEPA ® (icosapent ethyl) i...
2023-10-25 12:36:49 ET More on Amarin Amarin Corporation plc (AMRN) Cantor Fitzgerald Annual Amarin's Financial Tug-Of-War: Vascepa Vs. Generics Amarin in deal with Neopharm to sell Vazkepa in Israel Amarin up 6% on deal to sell Vazkepa in South Korea, SE Asi...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third qua...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
-- Greek Ministry of Health approved VAZKEPA ® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT ...
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect In...